Latest Regulatory Filings News

NSX Limited shareholders have overwhelmingly approved a scheme of arrangement for acquisition by a CNSX Markets-related entity, setting the stage for a significant market transition pending court approval.

The Royal Court of Jersey has approved Harmony Gold’s acquisition of MAC Copper, setting the stage for MAC’s trading suspension and delisting from ASX and NYSE.

Vonex Limited’s shares will be suspended from ASX trading following court approval of its acquisition by Maxo Telecommunications, marking a pivotal moment for the telecom services company.

One Click Group has locked in $1.25 million through a share placement, bringing Thorney Investment Group on board as a major shareholder and accelerating its Cash Advance product launch.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

ReNerve Ltd is rapidly advancing its nerve repair product portfolio, with four ranges expected on the market by the end of 2025 and expanding global distribution. Clinical studies highlight significant patient benefits, supporting the company’s growth in a booming biomaterials market.

Vonex Limited shareholders have overwhelmingly approved Maxo Telecommunications’ acquisition scheme, setting the stage for a court decision that could delist Vonex from the ASX.

Neurizon Therapeutics has raised $5 million through an institutional placement to advance its lead ALS drug candidate NUZ-001 into a pivotal clinical trial, pending FDA clearance. The capital injection also supports manufacturing and pre-clinical development efforts.

News Corporation has completed a $450 million secondary offering of Class B shares by key Murdoch family trusts, alongside a new stockholders agreement that reshapes family voting power and share transfer rights.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Ian Ferrier, founder and long-standing board member of Energy One Limited, has sold a portion of his shares but reassures investors of his ongoing commitment to the company.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.